Published online Nov 26, 2021. doi: 10.12998/wjcc.v9.i33.10198
Peer-review started: July 9, 2021
First decision: August 8, 2021
Revised: August 9, 2021
Accepted: September 10, 2021
Article in press: September 10, 2021
Published online: November 26, 2021
Statin and metformin are widely used medications in patients with type 2 diabetes mellitus (T2DM). These medications have been claimed as causative agents for neuropathy.
To identify the incidence and risk of statin, metformin and statin + metformin therapy on new onset neuropathy.
The incidence of neuropathy was evaluated and compared between T2DM patients who used or did not use statin/metformin/statin + metformin by using Korean Health Insurance Review and Assessment - national patient sample data.
The prospective cohort study used nation-wide health insurance data.
Statin therapy showed a positive association (odds ratio = 1.22, 95% confidence interval: 1.08-1.38], whereas metformin therapy showed a negative association with new onset neuropathy (odds ratio = 0.30, 95% confidence interval: 0.21-0.42) in patients with T2DM. Combination therapy of statin and metformin did not have an effect on new onset neuropathy of T2DM patients.
The widely used medications in T2DM, statin and metformin, could have an effect on neuropathy development in T2DM patients. Physicians should pay attention to new onset neuropathy when using statin in T2DM patients.
Nevertheless, further studies are required to reveal underlying mechanisms of statin and metformin on new onset neuropathy of T2DM.